NTLA-2001, first in-body CRISPR editing (2021)
Intellia Therapeutics and Regeneron dosed the first patients with CRISPR delivered by lipid nanoparticle to the liver, targeting the transthyretin gene. Earlier CRISPR trials edited cells outside the body and reinfused them. This one edited inside the patient.
Protein levels dropped sharply within weeks of a single infusion.
The delivery method became the template for liver-targeted editing, including CTX310.
CTX310 uses the same route and organ: an infusion that reaches the liver and turns off a gene there.
